The short-, medium- and long-term risk and the multi-organ involvement of clinical sequelae after COVID-19 infection: a multinational network cohort study

Ivan Chun Hang Lam, Yi Chai, Kenneth Keng Cheung Man, Wallis Cheuk Yin Lau, Hao Luo, Xiaoyu Lin, Can Yin, Celine Sze Ling Chui, Xue Li, Qingpeng Zhang, Esther Wai Yin Chan, Eric Yuk Fai Wan*, Ian Chi Kei Wong*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (SciVal)
2 Downloads (Pure)

Abstract

Objectives:
To generate comprehensive evidence on the risk of clinical sequelae involving different organ systems over time after coronavirus disease 2019 (COVID-19) infection.

Design:
Multinational retrospective cohort study.

Setting:
Electronic medical records from the US, UK, France, Germany and Italy standardised to the Observational Medical Outcomes Partnership Common Data Model.

Participants:
A total of 303,251 individuals with a COVID-19 infection between 1 December 2019 and 1 December 2020 and propensity score matched non-COVID-19 comparators from 22,108,925 eligible candidates.

Main outcome measures:
Incidence of 73 clinical sequelae involving multiple organ systems including the respiratory, cardiovascular, dermatological and endocrine systems over the short- (0–6 months), medium- (6–12 months) and long-term (1–2 years) after COVID-19 infection. The hazard ratio (HR) and 95% confidence interval (95% CI) of individual disease outcomes were estimated using Cox proportional hazard regression.

Results:
Individuals with COVID-19 incurred a greater risk of clinical sequelae involving multiple organ systems including respiratory (France HR 2.23, 95%CI [2.10,2.37] to Italy 13.13 [11.80,14.63]), cardiovascular (Germany 1.39 [1.30,1.50] to US 1.79 [1.74,1.85]) and dermatological (UK 1.13 [1.01,1.25] to Italy 1.77 [1.42,2.21]) disorder over the short-term. While the risk of clinical sequelae has largely subsided during the medium-term, the risk of cardiovascular- (US 1.16 [1.11,1.21], France 1.10 [1.01,1.19]) and endocrine- (US 1.18 [1.12,1.24], Germany 1.15 [1.03,1.29]) related complications may continue to persist for up to two years.

Conclusions:
Through a network of multinational healthcare databases, this study generated comprehensive and robust evidence supporting the extensive multi-organ involvement of post-COVID-19 condition over the short-term period and the subside in risk for most complications over the medium- and long-term.
Original languageEnglish
Pages (from-to)213-229
Number of pages17
JournalJournal of the Royal Society of Medicine
Volume118
Issue number7
Early online date8 Jul 2025
DOIs
Publication statusPublished - 8 Jul 2025

Bibliographical note

Copyright © The Royal Society of Medicine. This accepted manuscript version is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License [https://creativecommons.org/licenses/by-nc-nd/4.0/]. The published version is available at, 'Lam ICH, Chai Y, Man KKC, et al. (2025) The short-, medium- and long-term risk and the multi-organ involvement of clinical sequelae after COVID-19 infection: a multinational network cohort study. Journal of the Royal Society of Medicine', https://doi.org/10.1177/01410768251352666.

Keywords

  • COVID-19
  • SARS-CoV-2
  • post-COVID-19 conditions
  • long COVID
  • post-acute sequelae of SARS-CoV-2

Fingerprint

Dive into the research topics of 'The short-, medium- and long-term risk and the multi-organ involvement of clinical sequelae after COVID-19 infection: a multinational network cohort study'. Together they form a unique fingerprint.

Cite this